2021
Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.
PDF Presentation | ASC0 Annual Meeting, June 4-8, 2021 | Virtual Meeting
James M. G. Larkin, MD, PhD, et al.
Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma.
PDF Presentation | ASC0 Annual Meeting, June 4-8, 2021 | Virtual Meeting
Sajeve Samuel Thomas, et al.
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
PDF Presentation | Journal of Clinical Oncology 2021 | DOI: 10.1200/JCO.21.00612. Available at https://ascopubs.org/doi/full/10.1200/JCO.21.00612.
Amod A. Sarnaik, MD; Omid Hamid, MD; Nikhil I. Khushalani, MD; Karl D. Lewis, MD; Theresa Medina, MD; Harriet M. Kluger, MD; Sajeve S. Thomas, MD; Evidio Domingo-Musibay, MD; Anna C. Pavlick, DO, MBA; Eric D. Whitman, MD; Salvador Martin-Algarra, MD, PhD; Pippa Corrie, PhD; Brendan D. Curti, MD; Judit Oláh, MD, DSc; Jose Lutzky, MD; Jeffrey S. Weber, MD, PhD; James M. G. Larkin, MD, PhD; Wen Shi, MD, PhD; Toshimi Takamura, BA, BS; Madan Jagasia, MD; Harry Qin, PhD; Xiao Wu, PhD; Cecile Chartier, PhD; Friedrich Graf Finckenstein, MD; Maria Fardis, PhD, MBA; John M. Kirkwood, MD; and Jason A. Chesney, MD, PhD
Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced (unresectable or metastatic) melanoma: durable duration of response at 28 month follow-up
PDF Presentation | AACR Annual Meeting, Apr. 10-15, 2021 | Virtual Meeting
Jason Alan Chesney, MD, PhD, et al.
Trial in Progress: A Phase 2, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN-145) cell therapy in patients with metastatic non-small cell lung cancer (IOV-LUN-202)
PDF Poster | AACR Annual Meeting, Apr. 10-15, 2021 | Virtual Meeting
Erminia Massarelli, MD, PhD, et al.
Trial in Progress: A Phase 2, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145/LN-145-S1) in patients with solid tumors (IOV-COM-202)
PDF Poster | AACR Annual Meeting, Apr. 10-15, 2021 | Virtual Meeting
Scott Gettinger, MD, et al.
Trial in Progress: A Phase 1/2 study evaluating the safety and efficacy of IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (IOV-CLL-01)
PDF Poster| AACR Annual Meeting, Apr. 10-15, 2021 | Virtual Meeting
Meixiao Long, MD, PhD, et al.
2020
Safety and efficacy of tumor infiltrating lymphocytes (TIL; LN-145) in combination with pembrolizumab for advanced, recurrent or metastatiHNSCC
PDF Poster | SITC Annual Meeting, Nov. 9-14, 2020 | Virtual Meeting
Antonio Jimeno, Sophie Papa, Missak Haigentz, Juan F. Rodriguez-Moreno, Julian Schardt, Maria Fardis, Friedrich Graf Finckenstein, Rana Fiaz, Guang Chen, Alex Cacovean, Zelanna Goldberg, Ammar Sukari
In vivo persistence of Iovance tumor-infiltrating lymphocytes LN-145 in cervical cancer patients
PDF Poster | ESMO Congress, Sept. 19-21, 2020 | Virtual Meeting
Amir Jazaeri, Viktoria Gontcharova, Michelle Blaskovich, Kranthi Kunkalla, Emma Masteller, Maria Fardis, Cécile Chartier
Genetic Modification of Iovance’s TIL through TALEN-mediated knockout of PD-1 as a strategy to empower TIL therapy for cancer
PDF Poster | ESMO Congress, Sept. 19-21, 2020 | Virtual Meeting
Krit Ritthipichai, Marcus Machin, Shwetha Lakshmipathi, Alexandre Juillerat, Laurent Poirot, Maria Fardis, Cécile Chartier
Iovance Generation-2 Tumor-infiltrating Lymphocyte (TIL) Product Is Reinvigorated During the Manufacturing Process
PDF Poster | ESMO Congress, Sept. 19-21, 2020 | Virtual Meeting
Michelle R. Simpson-Abelson, Angel Cedano-Hilton, Kenneth D’Arigo, Maria Fardis, Cécile Chartier
Expert Insight – Current and future directions for tumor infiltrating lymphocyte therapy for the treatment of solid tumors
PDF Article | Cell & Gene Therapy Insights 2020; 6(6), 855–863 DOI: 10.18609/cgti.2020.088
Maria Fardis, Kelly DiTrapani, Cécile Chartier, Friedrich Graf Finckenstein
Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies
PDF Presentation | ASCO Annual Meeting, May 29-30, 2020 | Virtual Meeting
Amod Sarnaik, MD, H. Lee Moffitt Cancer Center, Tampa, FL
2019
Lifileucel, a Potential Therapy for Metastatic Melanoma Patients who are Primary Refractory to Prior Anti-PD-1 Therapy
PDF Poster | SMR Annual Meeting, November 20-23, 2019 | Salt Lake City
Amod Sarnaik, Nikhil I. Khushalani, Jason Alan Chesney, Harriet M. Kluger, Karl D. Lewis, Theresa Medina, Evidio Domingo-Musibay, Anna C. Pavlick, Eric D. Whitman, Salvador Algarra, Pippa Corrie, Omid Hamid, Jose Lutzky, Judit Oláh, Jeffrey S. Weber, James M. G. Larkin, Wen Shi,Kelly DiTrapani, Harry Qin, Renee Wu, Friedrich Graf Finckenstein, Maria Fardis, John M. Kirkwood
Iovance Gen 2 TIL Manufacturing Process Produces Drug Products that Exhibit Favorable Quality Attributes for Adoptive Cell Transfer Across 5 Solid Tumor Indications
PDF Poster | SITC Annual Meeting, November 6-10, 2019 | National Harbor, MD
Seth Wardell, Maritza Lienlaf-Moreno, Michelle Blaskovich, Ian Frank, Virginia Van Grod, Maria Fardis and Joseph Wypych
Safety and efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update
PDF Poster | SITC Annual Meeting, November 6-10, 2019 | National Harbor, MD
Amod Sarnaik, Nikhil I. Khushalani, Jason Alan Chesney, Harriet M. Kluger, Brendan D. Curti, Karl D. Lewis, Theresa Medina, Sajeve Samuel Thomas, Anna C. Pavlick, Eric D. Whitman, Salvador Algarra, Pippa Corrie, Omid Hamid, Jose Lutzky, Judit Oláh, DSc, Jeffrey S. Weber, James M. G. Larkin, Wen Shi, Kelly DiTrapani, Harry Qin, Mariam Mirgoli, Renee Wu, Toshimi Takamura, Maria Fardis, John M. Kirkwood
Expanding Iovance’s tumor infiltrating lymphocytes (TIL) from core biopsies for adoptive T cell therapy using a 22-day manufacturing process
PDF Poster | SITC Annual Meeting, November 6-10, 2019 | National Harbor, MD
Michelle R. Simpson-Abelson, Angel Hilton, Kenneth D’Arigo, Maria Fardis, and Cécile Chartier
Silencing PD-1 using PH-762 (PD-1 targeting INTASYL compound) to improve Iovance TIL effector function using Gen 2 manufacturing method
PDF Poster | SITC Annual Meeting, November 6-10, 2019 | National Harbor, MD
Inbar Azoulay Alfaguter, Michelle Simpson-Abelson, Krit Ritthipichai, Kenneth D’Arigo, Florangel Hilton, Marcus Machin, Dingxue Yan, James Cardia, Maria Fardis, and Cécile Chartier
Iovance Peripheral Blood Lymphocytes (PBL): A Potential Cell Therapy Strategy For The Treatment of Chronic Lymphocytic Leukemia
PDF Poster | European Hematologic Association Annual Congress – June 13-16, 2019 | Amsterdam
Lavakumar Karyampudi, Michelle Blaskovich, Ian Frank, Nermin Gerges, Amanda Stramer, Arvind Natarajan, Meixiao Long, Cecile Chartier, John Byrd, Maria Fardis
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1
PDF Poster | ASCO Annual Meeting, May 31 – June 4, 2019 | Chicago
Amod Sarnaik, Nikhil I. Khushalani, Jason Alan Chesney, Harriet M. Kluger, Brendan D. Curti, Karl D. Lewis, Sajeve Samuel Thomas, Eric D. Whitman, Omid Hamid, Jose Lutzky, Anna C. Pavlick, Jeffrey S. Weber, James M.G. Larkin, Debora Barton, Kelly DiTrapani, Renee Wu, Maria Fardis, John M. Kirkwood
Safety & efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma
PDF Poster | ASCO Annual Meeting, May 31 – June 4, 2019 | Chicago
Amir A. Jazaeri, Emese Zsiros, Rodabe Navroze Amaria, Andrew S. Artz, Robert P. Edwards, Robert Michael Wenham, Brian M. Slomovitz, Axel Walther, Sajeve Samuel Thomas, Jason Alan Chesney, Robert Morris, Koji Matsuo, Stephanie Gaillard, Peter G. Rose, Jesus Garcia Donas, Jacqueline Maria Tromp, Kelly DiTrapani, Huiling Li, Maria Fardis, Bradley J. Monk
A Phase 2 study of autologous tumor infiltrating lymphocytes (TIL; lifileucel [LN-144]/LN-145) in patients with solid tumors
PDF Poster | ASCO Annual Meeting, May 31 – June 4, 2019 | Chicago
Jason Chesney, Jose Lutzky, Sajeve Samuel Thomas, Jorge Nieva, Eva Muñoz Couselo, Juan Francisco Moreno Rodriguez, Juan Jesus Martin-Liberal, Alex Cacovean, Huiling Li, Zelanna Goldberg, Maria Fardis, Scott Gettinger
Expansion of tumor-infiltrating lymphocytes (TIL) using Iovance’s Gen 2 process from bladder cancer for adoptive immunotherapy
PDF Poster | AACR Meeting – Bladder Cancer: Transforming the Field, May 18-21, 2019 | Denver
Qiang John Li, Khurshid Guru, Amit Lugade, Elizabeth Brese, Kunle Odunsi, Anand Veerapathran, Kenneth Onimus, Adrian Wells, Cécile Chartier, Arvind Natarajan, Maria Fardis, Gurkamal Chatta
Persistence of cryopreserved tumor-infiltrating lymphocyte product lifileucel (LN-144) in C-144-01 study of advanced metastatic melanoma
PDF Poster | AACR Annual Meeting, March 29-April 03, 2019 | Atlanta
Viktoria Gontcharova, Sam Suzuki, Michelle Abelson, Michelle Blaskovich, Cécile Chartier
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients following progression on checkpoint inhibitors
PDF Poster | ASCO-SITC Clinical Immuno-Oncology Symposium, February 28-March 02, 2019 | San Francisco
Amod Sarnaik, Sajeve Samuel Thomas, Diwakar Davar, John M. Kirkwood, Harriet Kluger, Jose Lutzky, Melissa Wilson, Anna C. Pavlick, Brendan Curti, Eric Whitman, Karl Lewis, Giao Phan, Omid Hamid, Evidio Domingo-Musibay, Marc Ernstoff, Hendrik-Tobias Arkenau, Judit Olah, Pippa Corrie, Stéphane Dalle, Salvador Algarra, Gregory Daniels, Lavakumar Karyampudi, Toshimi Takamura, Debora Barton, Sam Suzuki, Nancy L. Samberg, Maria Fardis, Jason Chesney
2018
Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients following progression on checkpoint inhibitorsPDF Poster | SITC Annual Meeting, November 9-11, 2018 | Washington, DC
Amod Sarnaik, Sajeve Samuel Thomas, Diwakar Davar, John M. Kirkwood, Harriet Kluger, Jose Lutzky, Melissa Wilson, Anna C. Pavlick, Brendan Curti, Eric Whitman, Karl Lewis, Giao Phan, Omid Hamid, Evidio Domingo-Musibay, Marc Ernstoff, Hendrik-Tobias Arkenau, Judit Olah, Pippa Corrie, Stéphane Dalle, Salvador Algarra, Gregory Daniels, Lavakumar Karyampudi, Toshimi Takamura, Debora Barton, Sam Suzuki, Nancy L. Samberg, Maria Fardis, Jason Chesney
PD1-positive tumor-infiltrating lymphocytes (TIL) for the next generation of adoptive T cell therapy
PDF Poster | SITC Annual Meeting, November 9-11, 2018 | Washington, DC
Michelle R. Simpson-Abelson, Kenneth D’Arigo, Angel Cedano-Hilton, Ian Frank, Viktoria Gontcharova, Krit Ritthipichai, and Cécile Chartier
A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma
PDF Poster | ASCO Annual Meeting, June 1-5, 2018 | Chicago
Amod Sarnaik, Brendan Curti, Diwakar Davar, John M. Kirkwood, Omid Hamid, Jose Lutzky, Melissa Wilson, Harriet Kluger, Eric Whitman , Giao Phan, Sajeve Samuel Thomas,Karl Lewis, Hendrik-Tobias Arkenau, Bente Larsen, Igor Gorbatchevsky, Corina Andresen, Sam Suzuki, Nancy Samberg, Maria Fardis, Jason Chesney
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
PDF Poster | ASCO Annual Meeting, June 1-5, 2018 | Chicago
Rom Leidner, Ammar Sukari, Christine Chung, James Ohr, Missak Haigentz, Ezra E. W. Cohen, Robert J. Brown, Igor Gorbatchevsky, Sam Suzuki, Maria Fardis, Robert L. Ferris
Trial in Progress: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma
PDF Poster | ASCO Annual Meeting, June 1-5, 2018 | Chicago
Amir Jazaeri, Robert Edwards, Robert Wenham, Koji Matsuo, Gini F. Fleming, David M. O’Malley, Brian Slomovitz, Bradley Monk, Robert J. Brown, Igor Gorbatchevsky, Sam Suzuki, Maria Fardis, Emese Zsiros MD
Trial in Progress: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma
PDF Poster | AACR Annual Meeting, April 14-18, 2018 | Chicago
Amir Jazaeri, Robert Edwards, Robert Wenham, Koji Matsuo, Gini F. Fleming, David M. O’Malley, Brian Slomovitz, Bradley Monk, Robert J. Brown, Igor Gorbatchevsky, Sam Suzuki, Maria Fardis, Emese Zsiros
Phase 2 Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combination with Anti-PD-L1 Inhibitor Durvalumab (MEDI4736) in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
PDF Poster | AACR Annual Meeting, April 14-18, 2018 | Chicago
Sylvia Lee, Liza Villaruz, Susie Tanamly, Igor Gorbatchevsky, Sam Suzuki, Maria Fardis, Missak Haigentz
Activating OX40 receptor promotes the expression of CD8+ TIL with enhanced T-cell Effector Function
PDF Poster | AACR Annual Meeting, April 14-18, 2018 | Chicago
Krit Ritthipichai, Marcus Machin, Maria Fardis, and Cecile Chartier
2017
Novel Cryopreserved Tumor Infiltrating Lymphocytes (LN-144) Administered to Patients with Metastatic Melanoma Demonstrates Efficacy and Tolerability in a Multicenter Phase 2 Clinical Trial
PDF Poster | SITC Annual Meeting , November 8 2017 | National Harbor, MD
Amod Sarnaik, Jason Chesney, Harriet Kluger, Brendan Curti, Omid Hamid, Jose Lutzky, Maria Fardis, Igor Gorbatchevsky, Sam Suzuki, Bente Larsen, Nancy L. Samberg, John Kirkwood
A Cryopreserved Tumor Infiltrating Lymphocyte (TIL) Product for LN-144, Generated with an Abbreviated Method Suitable for High Throughput Commercial Manufacturing Exhibits Favorable Quality Attributes For Adoptive Cell Transfer
PDF Poster | SITC Annual Meeting , November 8 2017 | National Harbor, MD
Seth Wardell, Ian Frank, Lavakumar Karyampudi, Anand Veerapathran, Michelle Simpson-Abelson, Maritza Lienlaf Moreno, Michelle Blaskovich, Joseph Wypych, and Maria Fardis
Studies of Key Quality Attributes for TIL Product, LN-144
PDF Poster | SITC Annual Meeting , November 8 2017 | National Harbor, MD
Krit Ritthipichai, Ian Frank, Marcus Machin, Michelle Blaskovich, Amanda Stramer, Michelle Simpson-Abelson, Maria Fardis, Cecile Chartier
A phase 2 study to evaluate the safety and efficacy of using autologous tumor infiltrating lymphocytes (LN -145) in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
PDF Poster | SITC Annual Meeting , November 8 2017 | National Harbor, MD
Leidner R, Ohr J, Chung C, Brown RJ, Suzuki S, Gorbatchevsky I, Fardis M, and Ferris RL
A phase 2, multicenter study to evaluate the efficacy and safety of using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma
PDF Poster | SITC Annual Meeting , November 8 2017 | National Harbor, MD
Amir Jazaeri, Robert Edwards, Emese Zsiros, Robert Brown, Igor Gorbatchevsky, Sam Suzuki, Maria Fardis, Robert Wenham
The T-cell Growth Factor Cocktail IL-2/IL-15/IL-21 Enhances Expansion and Effector Function of Tumor-Infiltrating T cells in a Novel Process Developed by Iovance
PDF Poster | SITC Annual Meeting , November 8 2017 | National Harbor, MD
Michelle R. Simpson-Abelson, Christopher Mosychuk, Ian Frank, Krit Ritthipichai, and Cecile Chartier
Phenotypic and Functional Characterization of Tumor Infiltrating Lymphocytes (TIL) Grown from Non-Hodgkin Lymphoma Tumors – Implications for the Development of Novel Therapies for Lymphoma
PDF Poster | ESMO Annual Meeting, September 7-12, 2017 | Madrid
Lavakumar Karyampudi, Aishwarya Gokuladass, Michelle Blaskovich, Maria Fardis, Michael T Lotze
Efficacy of Single Administration of Tumor Infiltrating Lymphocytes (TIL) in Heavily Pre-Treated Metastatic Melanoma Patients Following Checkpoint Therapy
PDF Poster | ASCO Annual Meeting 2017
Amod Sarnaik, Harriet Kluger, Jason Chesney, Jyothi Sethuraman, Michael T. Lotze, Bente Larsen, Igor Gorbatchevsky, Nancy L. Samberg, Sam Suzuki, Lei Wang, Mariam Mirgoli, Maria Fardis, Brendan Curti
K+ Channel Activation Promotes Tumor Infiltrating Lymphocyte (TIL) Expansion and Enhances Expression of CCR7
PDF Poster | AAI Annual Meeting 2017
Krit Ritthipichai, Marcus Machin, Michelle Simpson-Abelson, Christopher Mosychuk, Anand Veerapathran, and Michael T. Lotze
Emigrant Tumor Infiltrating Lymphocytes (TIL) Profoundly Differ from Remnant T-cells
PDF Poster | AACR Annual Meeting 2017
Michelle R. Simpson-Abelson, Christopher Mosychuk, Maria Fardis, and Michael T. Lotze
2016
Redirected lysis assay as an efficient potency assay to assess TILs for immunotherapy
PDF Poster | Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82, DOI 10.1186/s40425-016-0172-7
Aishwarya Gokuldass, Michelle A Blaskovich, Charlene Kopits, Brian Rabinovich, Michael T. Lotze
Remarkably Stable Tumor-Infiltrating Lymphocytes (TIL) for Infusion Phenotype Following Cryopreservation
PDF Poster | Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82, DOI 10.1186/s40425-016-0172-7
Ian Frank, Amanda Stramer, Michelle A Blaskovich, Seth Wardell, Maria Fardis, James Bender, Michael T Lotze
Successful expansion and characterization of tumor infiltrating lymphocytes (TILs) from non-melanoma tumors
PDF Poster | Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82, DOI 10.1186/s40425-016-0172-7
Jyothi Sethuraman, Laurelis Santiago, Jie Qing Chen, Zhimin Dai, Seth Wardell, James Bender, Michael T Lotze
Artificial antigen presenting cells promote expansion of tumor infiltrating lymphocytes (TILs)
PDF Poster | Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):82, DOI 10.1186/s40425-016-0172-7
Anandaraman Veerapathran, Aishwarya Gokuldass, Amanda Stramer, Jyothi Sethuraman, Michelle A Blaskovich, Doris Wiener, Ian Frank, Laurelis Santiago, Brian Rabinovich, Maria Fardis, James Bender, Michael T Lotze
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma
PubMed | Journal of Clinical Oncology 2016 34:20, 2389-2397, doi: 10.1200/JCO.2016.66.7220
Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM, Shelton TE, Lu L, Kwong MLM, Ilyas S, Klemen ND, Payabyab EC, Morton KE, Toomey MA, Steinberg SM, White DE, and Rosenberg SA
2015
Adoptive cell transfer as personalized immunotherapy for human cancer
Science 03 Apr 2015, Vol. 348, Issue 6230, pp. 62-68, DOI 10.1126/science.aaa4967
Rosenberg SA, and Restifo NP
Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.
Clin Cancer Res. 2015;21(3):611-21
Chacon JA, Sarnaik AA, Chen JQ, et al.
2014
Finding suitable targets is the major obstacle to cancer gene therapy
Cancer Gene Ther. 2014;21(2):45-7
Rosenberg SA
Exploiting the curative potential of adoptive T-cell therapy for cancer
Immunol Rev. 2014;257(1):56-71
Hinrichs CS, Rosenberg SA